If the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe please get in touch via Contact@EBiSC.org.

BIONi010-C-66

BIONi010-C-N7

Gene-edited iPSC line

Not-for-profit fee: £1700 per vial
Not released.
The cell line is not released.

General#

Cell Line

hPSCreg name BIONi010-C-66
Alternative name(s)
BIONi010-C-N7
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
BIONi010-C
(BIONi010-C, K3P53)
BIONi010-C-17
(BIONi010-C TREM2 KO)
BIONi010-C-13
(BIONi010-C + NGN2 #I7-26)
BIONi010-C-3
(BIONi010-C ApoE KO #KO30 P30)
BIONi010-C-15
(BIONi010-C +dox inducible NGN2-GFP)
BIONi010-C-25
(BIONi010-C heterozygous TREM2 KO)
BIONi010-C-10
(HNF1AP291fsinsC +/- 54-5)
BIONi010-C-11
(HNF1AP291fsinsC -/- 66-1)
BIONi010-C-12
(HNF4ApR309C -/- 2-4)
BIONi010-C-2
(BIONi010-C ApoE E3/E3 #H8 P32)
BIONi010-C-70
(BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-71
(BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-4
(BIONi010-C ApoE E4/E4 #B44 P27)
BIONi010-C-5
(BIONi010-C CD33 E2del #N14 P26)
BIONi010-C-6
(BIONi010-C ApoE E2/E2)
BIONi010-C-7
(BIONi010-C Trem2 R47H)
BIONi010-C-8
(BIONi010-C Trem2 T66M, #Y5-80)
BIONi010-C-9
(BIONi010-C CD33 KO)
BIONi010-C-24
(BIONi010-C Dox a-syn)
BIONi010-C-51
(BIONi010-C TNNI3-mCherry reporter)
BIONi010-C-18
(BIONi010-C TBK1 KO)
BIONi010-C-19
(BIONi010-C IKBKE KO)
BIONi010-C-52
(BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6))
BIONi010-C-53
(BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2))
BIONi010-C-55
(BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74)
BIONi010-A
(K1P53)
BIONi010-B
(K2P53, BIONi010-B)

Provider

Depositor Fraunhofer Institute for Biomedical Engineering IBMT (IBMT)
Owner Fraunhofer Institute for Biomedical Engineering IBMT
Distributors
EBiSC
Derivation country Germany

External Databases

hPSCreg BIONi010-C-66
BioSamples SAMEA111454172

General Information

This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of

Donor Information#

General Donor Information

Sex male
Ethnicity Black or African-American

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105780

hIPSC Derivation#

General

The source cell information can be found in the parental cell line BIONi010-C.
Passage number reprogrammed 48

Reprogramming method

Vector type Non-integrating
Vector Episomal
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 5 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Unknown
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Unknown
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Karyotype analysis revealed no chromosomal abnormalities
Passage number: 48
Karyotyping method: KaryoStat

Other Genotyping (Cell Line)

Genetic Modification#

Disease/phenotype related modifications
Synonyms
  • Cystic Fibrosis
  • cystic fibrosis
Genetic modifications
CFTR (target)
Gene knock-in
CRISPR-associated (CRISPR/Cas) System